The new PBS listing of Dovato will revolutionise accessibility and safety with HIV-1 treatment. Source: NIAID via Wikimedia Commons Global specialist HIV company, ViiV Healthcare has announced that a new fixed-dose combination for “treatment-naïve adults” and adolescents with HIV type 1 (HIV-1) will be reimbursed on the Pharmaceutical Benefits Scheme (PBS) from tomorrow, 1 December (World AIDS Day). The new once-daily single tablet, Dovato, contains the two active ingredients used to treat HIV-1 infection, Dolutegravir and Lamivudine. Under the PBS subsidy, Dovato will be used to treat HIV in people above 12 years of age who weigh at least 40 kg and have no known or suspected resistance to either antiretroviral components. Dolutegravir belongs to a group of antiretroviral medicines called integrase inhibitors (INIs) while Lamivudine is a nucleoside analogue reverse transcriptase inhibitor (NRTI). National Association of People With HIV Australia (NAPWHA) spokesperson Robert Mitchell said the decision to […]